Literature DB >> 19114681

Low-dose inhaled carbon monoxide attenuates the remote intestinal inflammatory response elicited by hindlimb ischemia-reperfusion.

Jeffrey R Scott1, Mark A Cukiernik, Michael C Ott, Aurelia Bihari, Amit Badhwar, Daryl K Gray, Kenneth A Harris, Neil G Parry, Richard F Potter.   

Abstract

Heme oxygenase (HO) represents the rate-limiting enzyme in the degradation of heme into carbon monoxide (CO), iron, and biliverdin. Recent evidence suggests that several of the beneficial properties of HO, may be linked to CO. The objectives of this study were to determine if low-dose inhaled CO reduces remote intestinal leukocyte recruitment, proinflammatory cytokine expression, and oxidative stress elicited by hindlimb ischemia-reperfusion (I/R). Male mice underwent 1 h of hindlimb ischemia, followed by 3 h of reperfusion. Throughout reperfusion, mice were exposed to AIR or AIR + CO (250 ppm). Following reperfusion, the distal ileum was exteriorized to assess the intestinal inflammatory response by quantifying leukocyte rolling and adhesion in submucosal postcapillary venules with the use of intravital microscopy. Ileum samples were also analyzed for proinflammatory cytokine expression [tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta] and malondialdehyde (MDA) with the use of enzyme-linked immunosorbent assay and thiobarbituric acid reactive substances assays, respectively. I/R + AIR led to a significant decrease in leukocyte rolling velocity and a sevenfold increase in leukocyte adhesion. This was also accompanied by a significant 1.3-fold increase in ileum MDA and 2.3-fold increase in TNF-alpha expression. Treatment with AIR + CO led to a significant reduction in leukocyte recruitment and TNF-alpha expression elicited by I/R; however, MDA levels remained unchanged. Our data suggest that low-dose inhaled CO selectively attenuates the remote intestinal inflammatory response elicited by hindlimb I/R, yet does not provide protection against intestinal lipid peroxidation. CO may represent a novel anti-inflammatory therapeutic treatment to target remote organs following acute trauma and/or I/R injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19114681     DOI: 10.1152/ajpgi.90243.2008

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  7 in total

Review 1.  Protective role of hemeoxygenase-1 in gastrointestinal diseases.

Authors:  Marisol Chang; Jing Xue; Vishal Sharma; Aida Habtezion
Journal:  Cell Mol Life Sci       Date:  2014-11-27       Impact factor: 9.261

Review 2.  Heme oxygenase-1 system and gastrointestinal inflammation: a short review.

Authors:  Xiao Zhu; Wen-Guo Fan; Dong-Pei Li; Hsiangfu Kung; Marie Cm Lin
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

Review 3.  Heme Oxygenase 1 in Vertebrates: Friend and Foe.

Authors:  Rafael Cardoso Maciel Costa Silva; Leonardo Holanda Travassos Correa
Journal:  Cell Biochem Biophys       Date:  2021-11-20       Impact factor: 2.194

Review 4.  CO and CO-releasing molecules (CO-RMs) in acute gastrointestinal inflammation.

Authors:  D Babu; R Motterlini; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Ginsenoside Rb1 attenuates intestinal ischemia/reperfusion‑induced inflammation and oxidative stress via activation of the PI3K/Akt/Nrf2 signaling pathway.

Authors:  Sufang Chen; Xiang Li; Yanling Wang; Panwei Mu; Chaojin Chen; Pinjie Huang; Dezhao Liu
Journal:  Mol Med Rep       Date:  2019-03-12       Impact factor: 2.952

Review 6.  Therapeutic applications of carbon monoxide.

Authors:  Melissa Knauert; Sandeep Vangala; Maria Haslip; Patty J Lee
Journal:  Oxid Med Cell Longev       Date:  2013-12-04       Impact factor: 6.543

Review 7.  Carbon Monoxide Being Hydrogen Sulfide and Nitric Oxide Molecular Sibling, as Endogenous and Exogenous Modulator of Oxidative Stress and Antioxidative Mechanisms in the Digestive System.

Authors:  Edyta Korbut; Tomasz Brzozowski; Marcin Magierowski
Journal:  Oxid Med Cell Longev       Date:  2020-04-15       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.